NATURAL ALTERNATIVES INTERNATIONAL INC

Natural Alternatives International, Inc.

As of June 30

(Dollars in thousands, except share and per share data)

Consolidated Statements of Operations and Comprehensive Loss

(Dollars in thousands, except share and per share data)

Consolidated Statements of Stockholders’** Equity**

(Dollars in thousands)

(in thousands)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

A. Organization and Summary of Significant Accounting Policies

Organization

We provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the U.S. We also seek to commercialize our patent and trademark estate related to the ingredient known as beta-alanine sold under our CarnoSyn®, SR CarnoSyn® and TriBsyn™ trademarks through raw material and finished product sales and various license and similar arrangements.

Subsidiaries

On* January**22,* 1999, Natural Alternatives International Europe S.A., a Swiss Corporation (NAIE) was formed as our wholly owned subsidiary, based in Manno, Switzerland. In* September 1999,*NAIE opened a manufacturing facility and currently possesses manufacturing capability in encapsulation, powders, tablets, finished goods packaging, quality control laboratory testing, warehousing, distribution and administration.

Principles of Consolidation

The consolidated financial statements include the accounts of Natural Alternatives International, Inc. (NAI) and our wholly owned subsidiary, NAIE. All intercompany accounts and transactions have been eliminated. The functional currency of NAIE, our foreign subsidiary, is the U.S. Dollar. Certain accounts of NAIE have been translated at either current or historical exchange rates, as appropriate, with gains and losses included in the consolidated statements of operations.

Recently Adopted Accounting Pronouncements

In* November 2023,the FASB issued ASU2023*-07, "Segment Reporting (Topic280): Improvements to Reportable Segment Disclosures". This amendment improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendment in this update is effective for fiscal years beginning after* December 15, 2023,and interim periods with fiscal years beginning after December 15, 2024.We adopted this guidance in fiscal2025* and will adopt the guidance in interim periods beginning in fiscal2026. The adoption of ASU2023-07 didnot materially impact our results of operations or our financial statement presentation or related disclosures.

Recently Issued Accounting and Regulatory Pronouncements

In* Novemberof2024,* the FASB issued ASU2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic220-40): Disaggregation of Income Statement Expenses. This ASU requires public companies to disclose, in the notes to financial statements, specified information about certain costs and expenses presented in the Consolidated Statements of Operations and Comprehensive Loss. ASU2024-03 is effective for annual reporting periods beginning after* December 15, 2026,and interim reporting periods beginning after December 15, 2027.ASU2024*-03 allows for early adoption and requires prospective application to financial statements issued for reporting periods after the effective date of ASU2024-03, and it allows for election to retrospectively adopt to any or all comparatively presented prior periods in the financial statements beginning before the effective date. This ASU will be adopted in our annual financial statements for the year ending* June 30, 2028.We are currently evaluating the impact of this standard; however, we donot* expect it to have a material impact on our Consolidated Financial Statements.

In* October 2023,the FASB issued Accounting Standards Update ("ASU")2023-06, "Disclosure Improvements - Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative". ASU2023*-06 clarifies or improves disclosure and presentation requirements on various disclosure areas, including the statement of cash flows, earnings per share, debt, equity, and derivatives. The amendments will align the requirements in the FASB Accounting Standards Codification (ASC) with the SEC’s regulations. The amendments in this ASU will be effective on the date the related disclosures are removed from Regulation S-X or Regulation S-K by the SEC, and willnot be effective if the SEC hasnot removed the applicable disclosure requirement by* June 30, 2027.Early adoption is prohibited. As we are currently subject to these SEC requirements, this ASU isnot* expected to have a material impact on our Consolidated Financial Statements or related disclosures.

In* December 2023,the FASB issued ASU2023*-09, "Income Taxes (Topic740): Improvements to Income Tax Disclosures". The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU2023-09 are effective for fiscal years beginning after* December 15, 2024,with early adoption permitted. This ASU will be adopted in our annual financial statements for the year ending June 30, 2026.We are currently evaluating the impact of this standard; however, we donot* expect it to have a material impact on our Consolidated Financial Statements.

Cash and Cash Equivalents

We consider all highly liquid investments with a maturity ofthree months or less when purchased to be cash equivalents.

25

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We use athree-level hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available under the circumstances.

The fair value hierarchy is broken down intothree levels based on the source of inputs. In general, fair values determined by Level1 inputs use quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access. We classify cash, cash equivalents, and marketable securities balances as Level1 assets. The approximate fair value of cash and cash equivalents, accounts receivable, accounts payable and short-term borrowings is equal to book value due to the short-term nature of these items. Fair values determined by Level2 inputs are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that arenot active and models for which all significant inputs are observable or can be corroborated, either directly or indirectly by observable market data. Level3 inputs are unobservable inputs for the asset or liability and include situations where there is little, if any, market activity for the asset or liability. These include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

Except for cash and cash equivalents, as of* June 30, 2025* and* June 30, 2024*, we didnot have any financial assets or liabilities classified as Level1. We classify derivative forward exchange contracts as Level2 assets and liabilities. The fair values were determined by obtaining pricing from our bank.

Fair value of derivative instruments classified as Level2 assets and liabilities consisted of the following (in thousands):

We also classify any outstanding line of credit and term loan balance as a Level2 liability, as the fair value is based on inputs that can be derived from information available in publicly quoted markets. As of* June 30, 2025*, we had $1.9 million outstanding on our line of credit and of $8.9 million outstanding on our term loan. As of* June 30, 2024*, we had $3.4 million outstanding on our line of credit and $9.2 million outstanding on our term loan. As of* June 30, 2025* and* June 30, 2024*, we didnot have any financial assets or liabilities classified as Level3. We didnot transfer any assets or liabilities between these levels during fiscal2025 or fiscal2024.

Accounts Receivable

We perform ongoing credit evaluations of our customers and adjust credit limits based on payment history and expected future customer credit-worthiness. An allowance for estimated credit losses is maintained based on, butnot limited to, historical collection experience, current customer financial condition, current and future economic and market conditions, and age of receivables to identify any customer credit issues. We monitor our expected collections regularly and adjust the allowance for credit loss accounts as necessary to recognize any changes in credit exposure. Upon conclusion that a receivable is uncollectible, we record the respective amount as a charge against allowance for credit losses. To date, such credit loss reserves, in the aggregate, have been adequate to cover collection losses.

Inventories

We operate primarily as a private-label contract manufacturer. We make products based upon anticipated demand or following receipt of customer specific purchase orders. From time to time, we make inventory for private-label contract manufacturing customers under a specific purchase order with delivery dates that* maysubsequently be rescheduled or canceled at the customer’s request. We value inventory at the lower of cost (first-in,first-out) or net realizable value on an item-by-item basis, including costs for raw materials, labor and manufacturing overhead. We establish reserves equal to all or a portion of the related inventory to reflect situations in which the cost of the inventory isnot* expected to be recovered. This requires us to make estimates regarding the market value of our inventory, including an assessment for excess and obsolete inventory. Once we establish an inventory reserve in a fiscal period, the reduced inventory value is maintained until the inventory is sold or otherwise disposed of. In evaluating whether inventory is stated at the lower of cost or net realizable value, management considers such factors as the amount of inventory on hand, the estimated time required to sell such inventory, the remaining shelf life and efficacy, the foreseeable demand within a specified time horizon and current and expected market conditions. Based on this evaluation, we record adjustments to cost of goods sold to adjust inventory to its net realizable value.

Property and Equipment

We state property and equipment at cost. Depreciation of property and equipment is provided using the straight-line method over their estimated useful lives, generally ranging from 1 to 39 years. We amortize leasehold improvements using the straight-line method over the shorter of the useful life of the improvement or the term of the lease. Maintenance and repairs are expensed as incurred. Significant expenditures that increase economic useful lives of property or equipment are capitalized and expensed over the useful life of such expenditure.

26

Impairment of Long-Lived Assets

We periodically evaluate the carrying value of long-lived assets to be held and used when events and circumstances indicate that the carrying amount of an asset* may**not* be recovered. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. During fiscal2025 and2024, we recognizedno impairment losses.

Derivative Financial Instruments

We* may*use derivative financial instruments in the management of our foreign currency exchange risk inherent in our forecasted sales denominated in Euros and Swiss Francs, our long-term lease liability denominated in Swiss Francs and our exposure to interest rate fluctuations related to our term-note with Wells Fargo.

We* mayhedge our foreign currency exposures by entering into offsetting forward exchange contracts. To the extent we use derivative financial instruments that meet the relevant criteria, we account for them as cash flow hedges. Foreign exchange derivative instruments that donot* meet the criteria for cash flow hedge accounting are marked-to-market through the Consolidated Statements of Operations and Comprehensive Loss. Historically, our cash flow derivative instruments related to our Euro sales have met the criteria for hedge accounting, while our derivative instruments related to our long-term lease liability havenot. In thefourth quarter of fiscal2025, we began hedging our currency risk associated with sales denominated in Swiss Franc and these derivative instruments meet the criteria for cash flow hedge accounting.

We recognize any unrealized gains and losses associated with derivative instruments accounted for as cash flow hedges in income in the period in which the underlying hedged transaction is realized. To the extent the derivative instrument is deemed ineffective we would recognize the resulting gain or loss in income at that time. As of* June 30, 2025*, we held derivative contracts designated as cash flow hedges primarily to protect against the foreign exchange risks inherent in our forecasted sales of products at prices denominated in currencies other than the U.S. Dollar, which are the Euro and Swiss Franc. As of* June 30, 2025*, the notional amounts of our foreign exchange contracts were $35.5 million (€31.2 million) for Euro sales and $6.8 million (CHF 5.4 million) for Swiss Franc sales. These contracts will mature over the next 11 months.

As of* June 30, 2025*, we held foreign currency contractsnot designated as cash flow hedges primarily to protect against changes in valuation of our long-term lease liability associated with our Swiss manufacturing and storage facilities. As of* June 30, 2025*, the notional amounts of our foreign currency contractsnot designated as cash flow hedges were $11.8 million (CHF 9.5 million). These contracts will mature in thefirst quarter of fiscal year2026.

We are exposed to interest rate fluctuations related to our $10.0 million Term Note with Wells Fargo, which carries a variable interest rate of 1.80% above the SOFR rolling30-day average. To manage our exposure to this variable rate, on* August 23, 2021,we entered into a floored interest rate swap that fixes our all-in rate on this loan to 2.4% for thefirst* three years of the term loan which expired on* September 3, 2024.*

Defined Benefit Pension Plan

We formerly sponsored a defined benefit pension plan. Effective* June**21,* 1999, we adopted an amendment to freeze benefit accruals to the participants. The plan obligation and related assets of the plan are presented in the notes to the consolidated financial statements. Plan assets, which consist primarily of marketable equity and debt instruments, are valued based uponthird party market quotations. Independent actuaries, through the use of a number of assumptions, determine plan obligations and annual pension expense. Key assumptions in measuring the plan obligations include the discount rate and estimated future return on plan assets. In determining the discount rate, we use an average long-term bond yield. Asset returns are based on the historical returns of multiple asset classes to develop a risk free rate of return and risk premiums for each asset class. The overall rate for each asset class was developed by combining a long-term inflation component, the risk free rate of return and the associated risk premium. A weighted average rate is developed based on the overall rates and the plan’s asset allocation.

Revenue Recognition

We record revenue based on afive-step model which includes: (1) identifying a contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price among the performance obligations; and (5) recognizing revenue as each of the various performance obligations are satisfied.

Revenue is measured as the net amount of consideration expected to be received in exchange for fulfillingone or more performance obligations. We identify purchase orders from customers as contracts. The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, including estimates for early payment discounts, volume rebates, and contractual discounts. Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. We review and update these estimates at the end of each reporting period, and the impact of any adjustment is recognized in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, we consider both the customer's ability and intent to pay the amount of consideration when it is due. Payment of invoices is due as specified in the underlying customer agreement, which is typically30 days from the invoice date. Invoices are generally issued on the date of transfer of control of the products ordered to the customer.

Revenue is recognized at the point in time that each of our performance obligations is fulfilled, and control of the ordered products is transferred to the customer. This transfer occurs when the product is shipped, or in some cases, when the product is delivered to the customer. We recognize revenue in certain circumstances before delivery to the customer has occurred (commonly referred to as bill-and-hold transactions). Products sold under bill-and-hold arrangements are recorded as revenue when risk of ownership has been transferred to the customer, but the product hasnot shipped due to a substantive reason, typically at the customer’s request. The product must be separately identified as belonging to the customer, ready for physical transfer to the customer, and we cannot have the ability to redirect the product to another customer.

We provide early payment discounts to certain customers. We evaluate the likelihood of customers taking advantage of these discounts based on historical payment trends. The cost of these discounts is reported as a reduction to the transaction price. If the actual discounts differ from those estimated, the difference is also reported as a change in the transaction price. We require prepayment from certain customers. We record any payments received in advance of contracts fulfillment as a contract liability, and they are classified as customer deposits on the consolidated balance sheet.

27

Contract liabilities and revenue recognized were as follows (in thousands):

Except for product defects,no right of return exists on the sale of our products. We estimate returns based on historical experience and recognize a returns liability for any estimated returns. As of* June 30, 2025*, we have $11,000 in our returns reserve.

We currently own certain U.S. patents, and each patent’s corresponding foreign patent applications. All of these patents and patent rights relate to the ingredient known as beta-alanine marketed and sold under our CarnoSyn®, SR CarnoSyn® and TriBsyn™ trademarks. We recorded beta-alanine raw material sales and royalty and licensing income as a component of revenue in the amount of $8.1 million during fiscal2025 and $8.4 million during fiscal2024. These royalty income and raw material sale amounts resulted in royalty expense paid to the original patent holders from whom NAI acquired its patents and patent rights. We recognized royalty expense as a component of cost of goods sold in the amount of $0.3 million during fiscal2025 and $0.3 million during fiscal2024.

Cost of Goods Sold

Cost of goods sold includes raw material, labor, manufacturing overhead, royalty expense, shipping, and customer related research and development costs.

Shipping and Handling Costs

We include fees earned on the shipment of our products to customers in sales and include costs incurred on the shipment of product to customers in costs of goods sold.

Research and Development Costs

As part of the services we provide to our private-label contract manufacturing customers, we* mayperform, but arenot* obligated to perform, certain research and development activities related to the development or improvement of their products. While our customers typically donot pay directly for this service, the cost of this service is included as a component of the price we charge to manufacture and deliver their products. We also direct and participate in clinical research studies, often in collaboration with scientists and research institutions, to validate the benefits of a product and provide scientific support for product claims and marketing initiatives.

Research and development costs are expensed when incurred. Our research and development expenses for the lasttwo fiscal years ended* June**30* were $1.8 million for fiscal2025 and $1.9 million for fiscal2024. These costs are included in selling, general and administrative expenses and cost of goods sold.

Advertising Costs

We expense the production costs of advertising thefirst time the advertising takes place. We incurred and expensed advertising costs in the amount of $0.4 million during the fiscal year ended* June 30, 2025* and $0.3 million during fiscal2024. These costs are included in selling, general and administrative expenses.

Income Taxes

To determine our annual provision for income taxes, we use an estimated annual effective tax rate that is based on annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions to which we are subject. We recognize interest and penalties related to uncertain tax positions, if any, as an income tax expense.

We record valuation allowances to reduce our deferred tax assets to an amount that we believe is more likely thannot to be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely thannot that some portion or all of the deferred tax assets will ultimately be realized based on whether future taxable income will be generated during the periods in which those temporary differences become deductible. During the year ended* June 30, 2025*, we recorded a valuation allowance against deferred income tax assets of $4.8 million, representing the amount of our deferred income tax assets in excess of our deferred income tax liabilities. We recorded the valuation allowance because management was unable to conclude, in light of the cumulative loss we have realized related to our US-based operations in recent years, that realization of the net deferred income tax asset was more likely thannot. The valuation allowance recorded during fiscal2025 primarily related to fiscal2025 and prior net operating loss carry forwards and changes in other deferred tax items recognized during fiscal2025. As a result of the recognition of these valuation adjustments, we have a $4.8 million net deferred tax asset offset by a valuation allowance of $4.8 million resulting in a net deferred tax asset of $0 as of* June 30, 2025*. This valuation allowance didnot have any effect on the tax expense and related liability recorded for operating income recognized by NAIE during the year ended* June 30, 2025*.

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured and recorded using enacted tax rates for each of the jurisdictions in which we operate, and adjusted using the tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income or expense in the period that includes the enactment date.

We account for uncertain tax positions using the more-likely-than-not recognition threshold. It is our policy to establish reserves based on management’s assessment of exposure for certain positions taken in previously filed tax returns that* maybecome payable upon audit by tax authorities. Our tax reserves are analyzed quarterly, and adjustments are made as events occur that we believe warrant adjustments to the reserves. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of June 30, 2025* and* June 30, 2024*, we didnot record any tax liabilities for uncertain tax positions.

28

Stock-Based Compensation

Our current omnibus equity incentive plan that became effective* January 1, 2021 (the“2020* Plan”), which was approved by our stockholders at the Annual Meeting of Stockholders on* December 4, 2020.Under the2020* Plan, we* may*grant nonqualified and incentive stock options, restricted stock grants, restricted stock units, stock appreciation rights, and other stock-based awards to employees, non-employee directors and consultants.

We estimate the fair value of stock option awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that haveno vesting restrictions and are fully transferable. Option valuation models require the use of highly subjective assumptions. Black-Scholes uses assumptions related to volatility, the risk-free interest rate, the dividend yield (which we assume to be zero, as we havenot paid any cash dividends) and employee exercise behavior. Expected volatilities used in the model are based on the historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect in the period of grant. The expected life of stock option grants is derived from historical experience. The fair value of restricted stock shares granted is based on the market price of our common stock on the date of grant. We amortize the estimated fair value of our stock awards to expense over the related vesting periods.

We recognize forfeitures as they occur.

Use of Estimates

Our management has made a number of estimates and assumptions relating to the reporting of assets and liabilities, revenue and expenses, and the disclosure of contingent assets and liabilities to prepare these consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP). Actual results could differ from those estimates and our assumptions* may*prove to be inaccurate.

Net Loss per Common Share

We compute basic net loss per common share using the weighted average number of common shares outstanding during the year, and diluted net loss per common share using the additional dilutive effect of all dilutive securities. The dilutive impact of stock options and restricted shares account for the additional weighted average shares of common stock outstanding for our diluted net income per common share computation. We calculated basic and diluted net (loss) income per common share as follows (in thousands, except per share data):

We exclude the impact of restricted stock from the calculation of diluted net loss per common share in periods where we have a net loss or when their inclusion would be antidilutive. During the year ended* June 30, 2025*, we excluded 222,551 shares of unvested restricted stock. For the year ended* June 30, 2024* we excluded restricted stock totaling 232,574, as their impact would have been anti-dilutive.

Concentrations of Credit Risk

Financial instruments that subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. We place our cash and cash equivalents with highly rated financial institutions. Credit risk with respect to receivables is primarily concentrated with ourthree largest customers, whose receivable balances collectively represented 67.8% of gross accounts receivable at* June 30, 2025* and 72.6% at* June 30, 2024*.

Additionally, amounts due related to our beta-alanine raw material sales were 6.8% of gross accounts receivable at* June 30, 2025* and 4.4% of gross accounts receivable at* June 30, 2024*. Concentrations of credit risk related to the remaining accounts receivable balances are limited due to the number of customers comprising our remaining customer base.

B. Inventories

Inventories, net, consisted of the following at* June**30* (in thousands):

29

C. Property and Equipment

Property and equipment consisted of the following at* June**30* (dollars in thousands):

During fiscal year2025, we disposed of machinery and equipment primarily due to obsolescence with total original value of $3.945 million and related accumulated depreciation of $3.896 million resulting in a loss on disposal of assets of $49,000.

Depreciation and amortization expense was $4.6 million in both fiscal2025 and fiscal2024.

D. Leases

We currently lease our Vista, California and Lugano, Switzerland product manufacturing and support facilities. At the inception of a contract, we assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period of the contract, and (3) whether we have the right to direct the use of the asset during such time period. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

On* July 18, 2023,we entered into a Fourth Amendment to the Lease of our Vista, California manufacturing facility. The Fourth Amendment extends the term of the Lease by an additionalten years andfive* months commencing* April 1, 2024.The amended lease coveringtwo* buildings and approximately 162,000 square feet will result in an increase in base rent to $1.50 per square foot, afterfive free months of base rent beginning at the commencement of the extended term. NAI intends to construct substantial improvements to the facilities including butnot limited to installation of an approximately $2.3 million solar electrical generating system on both buildings, and other substantial improvements. Pursuant to the Fourth Amendment, the Landlord will reimburse NAI for up to $1.1 million of these tenant improvements to the buildings. Our lease liability and right of use asset were both increased by approximately $25.9 million as a result of this lease extension effective on the date that the Fourth Amendment was executed.

On* January 26, 2024,we exercised the early termination of an apartment lease in Lugano, Switzerland. The early termination reduced the lease term by 9 years and8* months thus ending on* April 30, 2024.Our lease liability and right of use asset were both decreased by approximately $0.3 million as a result of the early termination of the lease agreement. On January 22,2024, we entered into a lease for a new apartment in Lugano, Switzerland. This lease is for an initial term of 27 months beginning April 1, 2024and ending on June 30, 2026.*

Leases are classified as either finance leases or operating leases. A lease must be classified as a finance lease if any of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset, or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it doesnot meet any of these criteria. Substantially all our operating leases are comprised of payments for the use of manufacturing and office space. We haveno leases classified as finance leases. As of* June 30, 2025*, the weighted average remaining lease term for our operating leases was 8.6 years. The weighted average discount rate for our operating leases was 5.94%. As of* June 30, 2024*, the weighted average remaining lease term for our operating leases was 9.5 years and the weighted average discount rate was 5.92%. The lease discount rate is determined as the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease.

The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, our secured incremental borrowing rate for the same term as the underlying lease. For our real estate and other operating leases, we use our secured incremental borrowing rate.

Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease willnot be terminated early. Certain leases contain escalation clauses. Fixed escalation clauses are included in our calculation of right-of-use assets and operating lease liabilities. Escalation clauses based on the CPI (Consumer Price Index) arenot included in our calculation of right-of-use assets and operating lease liabilities because they cannot be readily determined.

Some of our manufacturing leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement and separated into lease and non-lease components based on the initial amount stated in the lease or standalone selling prices. Lease components are included in the measurement of the initial lease liability. Additional payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses, including real estate taxes and insurance, are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability.

30

Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that werenot included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense.

We have electednot to recognize right-of-use assets and lease liabilities for short-term leases that have a term of12 months or less. The effect of short-term leases on our right-of-use asset, lease liability, and the short-term lease cost for the years ended* June 30, 2025and2024* wasnot material.

Other information related to leases was as follows (in thousands) for the year ended* June 30,*

E. Other Comprehensive (Loss) Income

Other comprehensive (loss) income (“OCL” and “OCI”) consisted of the following at* June**30* (dollars in thousands):

F. Debt

We have had a credit line with Wells Fargo Bank, N.A (“Wells Fargo”) for many years. The credit line has been amended, modified, and extended several times, most recently on* June 20, 2025,when we entered into a Sixth Amendment to Credit Agreement. The Sixth Amendment waived all prior instances of non-compliance and preemptively waived anticipated non-compliance with covenants in the quarter ending June 30, 2025.The amended Credit Agreement extended the credit line to December 31, 2026,*decreased the maximum principal amount that can be borrowed from $12.5 million to $10.0 million, increased the interest rate on borrowings under the line of credit to 3.25%, increased the unused commitment fee to 0.375%, and added the Company’s powder processing facility in Carlsbad, California as security for the amended Credit Agreement. Our obligations under the Credit Agreement are also secured by our accounts receivable and other rights to payment, general intangibles, inventory, equipment, and fixtures.

The Sixth Amendment also included modifications to our covenants under the Credit Agreement, including (i) net lossnot greater than $250,000 for thefirst quarter of fiscal2026, a net lossnot greater than $750,000 for the first half of fiscal2026, and net income of at least $1.00 on a year to date basis starting with thethird quarter of fiscal2026 and each fiscal quarter thereafter; (ii) fixed charge coverage ratio calculated on a rolling4-quarter basis ofnot less than1.0 to 1.0 for thefirst quarter of fiscal2026 andnot less than 1.25 to1.0 for thesecond fiscal quarter of2026 and all quarters thereafter. Amounts outstanding that are subject to a fluctuating interest rate* may*be prepaid at any time without penalty.

31

Amounts outstanding under our credit line are subject to a fixed interest rate,* may*be prepaid at any time in minimum amounts of $100,000 subject to a prepayment fee equal to the sum of the discounted monthly differences between payment under a fixed rate versus payment under the variable rate for each month from the month of prepayment through the month in which the then applicable fixed rate term matures. There is an unused commitment fee of 0.375% required as part of the line of credit, and an extension fee of $20,000 was incurred upon execution of the Sixth Amendment.

We have a Term Note with Wells Fargo we entered into on* August 16, 2021to borrow part of the purchase price of our powder processing and warehouse property in Carlsbad, California. The Term Note is secured by afirst* mortgage on that property. The Term Note was in the original principal amount of $10.0 million and is aseven-year note with payments fully amortized based on atwenty-five year assumed term. Installment payments under this term loan commenced* October 1, 2021and continue through August 1, 2028with a final installment consisting of all remaining amounts due, is due September 1, 2028.Amounts outstanding on this note during the term of the agreement bear interest at the rate of 1.8% above the SOFR rolling30*-day average.

We also have credit approval with Wells Fargo Bank, which allows us to hedge foreign currency exposures up to12 months in the future, and we have credit approval with Bank of America which allows us to hedge foreign currency exposures up to24 months in the future.

As of* June 30, 2025*, we had $8.9 million outstanding under the Term Note. The future debt payments under the Term Note are as follows (in thousands):

For the quarter ended* June 30, 2025*, we werenot in compliance with the minimum net income and fixed charge coverage ratio covenants of our credit agreement, but these defaults were prospectively waived by the Sixth Amendment to our credit facility. We anticipate we willnot be able to comply with all of the covenants required under the modified Credit Agreement in thefirst half of fiscal2026, primarily related to the impact on the fixed charge coverage ratio calculation due to the unexpected recognition of the litigation expense and valuation allowance on our net deferred tax assets during thefourth quarter of fiscal2025. We have advised our lender and are currently negotiating a potential revision to our credit agreement. There can beno assurance we will be able to successfully complete the negotiation of a revised credit facility, or what the differences in amount, cost and other factors* may*be.

As of* June 30, 2025*, we had $1.9 million outstanding on our credit facility with Wells Fargo Bank. Our available borrowing capacity under the amended terms of our amended credit facility was $9.9 million as of* June 30, 2025*.

G. Income Taxes

During fiscal2025, we recorded U.S.-based domestic tax expense of $2.7 million and foreign tax expense of $0.1 million. During fiscal2024, we recorded U.S.-based domestic tax benefit of $2.2 million and negligible foreign tax benefit.

During fiscal2025, we recorded a valuation allowance against net domestic deferred income tax assets of $4.8 million, representing the amount of our deferred income tax assets in excess of our domestic deferred income tax liabilities. We recorded the valuation allowance because management was unable to conclude, in light of the cumulative loss we have realized related to our US-based operations in recent years, that realization of the net deferred income tax asset was more likely thannot. The valuation allowance recorded during fiscal2025 primarily related to fiscal2025 and prior net operating loss carry forwards and changes in other deferred tax items recognized during fiscal2025. As a result of the recognition of these valuation adjustments, we have a $4.8 million net deferred tax asset offset by a valuation allowance of $4.8 million resulting in a net deferred tax asset of $0 as of* June 30, 2025*. This valuation allowance didnot have any effect on the tax expense and related liability recorded for operating income recognized by NAIE during the year ended* June 30, 2025*.

The following is a geographical breakdown of loss before income taxes (in thousands):

The provision (benefit) for income taxes for the years ended* June**30* consisted of the following (in thousands):

32

Net deferred tax assets and deferred tax liabilities as of* June**30* were as follows (in thousands):

As of* June 30,2025, the Company had U.S. federal net operating loss carryforwards of $8.0 million which maybe carried forward indefinitely. The Company has state net operating loss carryforwards of $6.8 million, which, if unutilized, will begin to expire beginning in fiscal year2032.* The Company has federal and state tax credits of $0.8 million, which, if unutilized, will begin to expire in fiscal year2041.

Pursuant to Section382 of the Internal Revenue Code of1986, as amended (the “Code”), the annual use of the net operating loss carry forwards and research and development tax credits could be limited by any greater than50% ownership change during anythree-year testing period. We didnot have any ownership changes that met this criterion during the fiscal years ended* June 30, 2025* and* June 30, 2024*.

We are subject to taxation in the U.S., Switzerland and various state jurisdictions. Our tax years for the fiscal year ended* June 30, 2020and forward are subject to examination by the U.S. tax authorities. Our tax years for the fiscal years ended June 30, 2019and forward are subject to examination by the state tax authorities. Our tax years for the fiscal year ended June 30, 2023*and forward are subject to assessment by the Swiss tax authorities.

NAIE’s effective tax rate for the fiscal year ended* June 30, 2025* for Swiss federal, cantonal and communal taxes is approximately 21%.

As part of the Tax Cuts and Jobs Act of2017 (the Tax Act), we were required to recognize aone-time deemed repatriation transition tax during the fiscal year ended* June 30, 2018based on our total post-1986 earnings and profits (E&P) from our Swiss subsidiary, NAIE. This accumulated E&P amount has historically been considered permanently reinvested thereby allowing us to defer recognizing any U.S. income tax on the amount. Weno* longer consider undistributed foreign earnings from NAIE as of* December 31, 2017as indefinitely reinvested. We consider earnings accumulated subsequent to December 31, 2017*as indefinitely reinvested.

For tax years commencing on or after* January 1, 2022,the Tax Cuts and Jobs Act of2017,* also eliminated the ability to immediately deduct research and development costs. Instead, taxpayers were mandated to capitalize these expenses and amortize them overfive years for research conducted within the United States and15 years for research conducted abroad, as stipulated in IRC Section174. Although the requirements of the Tax Cuts and Jobs Act of2017 are applicable for our fiscal year ended on* June 30, 2025*, the One Big Beautiful Bill Act was voted into law by congress on* July 4, 2025and restores the immediate expensing of domestic research and development expenses while making permanent the capitalization and amortization rules of research and development conducted abroad. The One Big Beautiful Bill Act is effective beginning in our fiscal year2026.* No dividends to NAI were declared by NAIE in fiscal2025. During fiscal2024, NAIE declared a dividend to NAI of $5.4 million, which was paid in thefirst quarter of fiscal2025. These amounts are part of the undistributed earnings that we recorded aone-time deemed repatriation transition tax in fiscal2018, and therefore, we didnot recognize any additional tax on these dividends. However, as part of these dividends, we were required to pay a 5% Swiss withholding tax totaling $0.3 million in fiscal2024 which was also accrued for as part of the implementation of the Tax Act in fiscal2018.

33

A reconciliation of our income tax provision (benefit) computed by applying the statutory federal income tax rate of 21% for fiscal2025 and for fiscal2024 to net loss before income taxes for the year ended* June**30* is as follows (dollars in thousands):

We expect our U.S. federal statutory rate to be 21% for fiscal years going forward.

H. Employee Benefit Plans

401(k) Plan

We have a profit-sharing plan pursuant to Section401(k) of the Code, whereby participants* maycontribute a percentage of compensationnot* in excess of the maximum allowed under the Code. Effective* January 1, 2022,all employees became eligible to participate in the plan thefirst* of the month following30 days of employment. Also effective,* January 1, 2025,we match 50% of thefirst* 6% of a participant’s compensation contributed to the plan. The total contributions under the plan charged to income from operations totaled $0.5 million for fiscal2025 and $0.6 million for fiscal2024.

Additionally, we have a discretionary profit-sharing plan pursuant to Section401(k) of the Code, whereby we* maycontribute an additional percentage of compensation. Employees arenot* required to contribute to the plan to receive the discretionary profit-sharing contribution. We didnot make any discretionary profit-sharing contributions in fiscal2025 or in fiscal2024.

We have a “Cafeteria Plan” pursuant to Section125 of the Code, whereby health care benefits are provided for active employees through insurance companies. Substantially all active full-time employees are eligible for these benefits. We recognize the cost of providing these benefits by expensing the annual premiums, which are based on benefits paid during the year. The premiums expensed to results from operations for these benefits totaled $1.6 million for the fiscal year ended* June 30, 2025* and $1.4 million for the fiscal year ended* June 30, 2024*.

Deferred Compensation Plan

Effective* July 16, 2020,the Board of Directors approved and adopted a Non-Qualified Incentive Plan (the “Incentive Plan”). Pursuant to the Incentive Plan, the Human Resources Committee and the Board of Directors may*make deferred cash payments or other cash awards (“Awards”) to directors, officers, employees and eligible consultants of NAI (“Participants”). These Awards are made subject to conditions precedent that must be met before NAI is obligated to make the payment. The purpose of the Incentive Plan is to enhance the long-term stockholder value of NAI by providing the Human Resources Committee and the Board of Directors the ability to make deferred cash payments or other cash awards to encourage Participants to serve NAI or to remain in the service of NAI, or to assist NAI to achieve results determined by the Human Resources Committee or the Board of Directors to be in NAI's best interest.

The Incentive Plan authorizes the Human Resources Committee or the Board of Directors to grant to, and administer, unsecured and deferred cash Awards to Participants and to subject each Award to whatever conditions are determined appropriate by the Human Resources Committee or the Board of Directors. The terms of each Award, including the amount and any conditions that must be met to be entitled to payment of the Award are set forth in an Award Agreement between each Participant and NAI. The Incentive Plan provides the Board of Directors with the discretion to set aside assets to fund the Incentive Plan although that hasnot been done to date.

During the year ended* June 30, 2025*, we granted a total of $0.2 million in deferred cash awards to members of our Board of Directors. During the year ended* June 30, 2024*, we granted a total of $0.9 million in deferred cash awards to members of our Board of Directors and certain key members of our management team. Each deferred cash award provides forthree equal cash payments to the applicable Participant to be paid on theone year,two year, andthree year anniversaries of the date of the grant of such Awards, (the “Award Date”); provided on the date of each payment (the “Payment Date”), the Participant has been since the Award Date, and continues to be through the Payment Date, a member of our Board of Directors or an employee of NAI. In the event a Participant ceases to be an employee of NAI or a member of our Board of Directors prior to any Payment Date,no further payments shall be made in connection with the Award.

No deferred cash awards were forfeited during the fiscal year ended* June 30, 2025* and the fiscal year ended* June 30, 2024*.

Defined Benefit Pension Plan

We formerly sponsored a defined benefit pension plan, which provides retirement benefits to employees based generally on years of service and compensation during the last five years before retirement. Effective* June**21,* 1999, we adopted an amendment to freeze benefit accruals to the participants. Annually, we contribute an amountnot less than the minimum funding requirements of the Employee Retirement Income Security Act of1974 nor more than the maximum tax-deductible amount.

34

Disclosure of Funded Status

The following table sets forth the defined benefit pension plan’s funded status and amount recognized in our consolidated balance sheets at* June**30* (in thousands):

The weighted-average discount rate used for determining the projected benefit obligations for the defined benefit pension plan was 5.29% for the year ended* June 30, 2025* and 5.28% during the year ended* June 30, 2024*.

Net Periodic Benefit Cost

The components included in the defined benefit pension plan’s net periodic benefit expense for the fiscal years ended* June**30* were as follows (in thousands):

In the fiscal year ended* June 30, 2025*, we contributed $48,000 to our defined benefit pension plan, and in the fiscal year ended* June 30, 2024*, we contributed $116,000 to our defined benefit pension plan.

The following is a summary of changes in plan assets and benefit obligations recognized in other comprehensive income (loss) (in thousands):

The estimated net loss for the defined benefit pension plan that will be amortized from accumulated other comprehensive income into net periodic benefit cost over the next fiscal year is approximately $17,000. We donot have any transition obligations or prior service costs recorded in accumulated other comprehensive income.

The following benefit payments are expected to be paid (in thousands):

35

The weighted-average rates used for the years ended* June**30* in determining the defined benefit pension plan’s net pension costs, were as follows:

Our expected rate of return is determined based on a methodology that considers historical returns of multiple classes analyzed to develop a risk-free real rate of return and risk premiums for each asset class. The overall rate for each asset class was developed by combining a long-term inflation component, the risk-free real rate of return, and the associated risk premium. A weighted average rate was developed based on those overall rates and the target asset allocation of the plan.

Our defined benefit pension plan’s weighted average asset allocation at* June**30* and weighted average target allocation were as follows:

The underlying basis of the investment strategy of our defined benefit pension plan is to ensure that pension funds are available to meet the plan’s benefit obligations when due. Our investment strategy is a long-term risk controlled approach using diversified investment options with relatively minimal exposure to volatile investment options like derivatives.

The fair values by asset category of our defined benefit pension plan at* June 30, 2025* were as follows (in thousands):

**I. Stockholders'**Equity

Treasury Stock

On* September 18, 2020,the Board of Directors authorized a $2.0 million increase to our stock repurchase plan (“Repurchase Plan”), thus bringing the total authorized repurchase amount to $12.0 million. On March 12, 2021,the Board of Directors authorized an additional $3.0 million increase to the Repurchase Plan, thus bringing the total authorized repurchase amount to $15.0 million. On January 14, 2022,the Board of Directors authorized an additional $3.0 million increase to the Repurchase Plan, thus bringing the total authorized repurchase amount to $18.0 million. Under the Repurchase Plan, we may,from time to time, purchase shares of our common stock, depending upon market conditions, in open market or privately negotiated transactions. Our Credit Agreement with Wells Fargo as amended, currently prohibits most stock repurchases (see Note F). As a result, until that restriction is modified or removed, we donot* intend to purchase our shares other than our longstanding practice of purchasing shares from our employees in exchange for paying the employees’ withholding tax requirements upon vesting of restricted stock held by the employee.

Treasury Stock repurchases for the year ended* June 30, 2025* were as follows:

36

Treasury Stock repurchases for the year ended* June 30, 2024* were as follows:

Treasury stock repurchase costs include commissions and fees.

Shares acquired from employees for restricted stock vesting were returned to us by the related employees and in return we paid each employee’s required tax withholding resulting from the vesting of restricted shares. The valuation of the shares acquired and thereby the number of shares returned to us was calculated based on the closing share price on the date the shares vested.

Stock Incentive Plans

For the years ended* June 30, 2025* and* June 30, 2024*, the Company hadno stock options outstanding.

Restricted stock activity for the year ended* June 30, 2025* was as follows:

Restricted stock activity for the year ended* June 30, 2024* was as follows:

Restricted stock grants, granted to members of our Board of Directors and certain key members of our management team, vest over a period of up tothree years from the date of grant and the unvested shares cannot be sold or otherwise transferred and the right to receive dividends, if declared by our Board of Directors, is forfeitable until the shares become vested. The total remaining unrecognized compensation cost related to unvested restricted stock shares amounted to $0.9 million at* June 30, 2025* and the weighted average remaining requisite service period of unvested restricted stock shares was 1.6 years.

J. Commitments

We lease a total of approximately 162,000 square feet at our manufacturing facility in Vista, California from an unaffiliatedthird party under a non-cancelable operating lease. On* July 18, 2023,we entered into afourth* amendment to the lease of our Vista, California manufacturing facility. Thefourth amendment extends the term of the lease by an additionalten years andfive months commencing* April 1, 2024and includes an option to extend the lease through August 31, 2039.*

NAIE leases facility space in Manno, Switzerland fromtwo unaffiliatedthird parties. The leased spaces total approximately 116,000 square feet**.We primarily use the facilities for manufacturing, packaging, warehousing and distributing nutritional supplement products for the European and Asian marketplaces. On May 4, 2022,NAIE further extended the lease on its main manufacturing facility for a new term often years effective January 1, 2023with a new expiration date of December 31, 2032,with an option to extendone year.

On* November 5, 2018,NAIE entered into a lease with Sofinol SA for approximately 2,870 square meters of commercial warehouse space in a building located on the property adjacent to the leasehold for the primary existing NAIE facility in Manno, Switzerland. NAIE uses the space primarily for raw material storage. The lease was for an initial five-year term commencing on January 1, 2019and NAIE can terminate the lease with12* months advance notice given on* June30th* or* December31st* each year of the initial term. At the end of the initial term the lease transfers to an indefinite tenancy at the same rental rate terminable by NAIE or the landlord upon12 months' advance notice. This initial term of this lease ended on* December 31, 2024and as of June 30, 2025*, we havenot provided notification of terminating this lease, so the term automatically extended to* December 31, 2026.*

37

On* January 26, 2024,we exercised the early termination of an apartment lease in Lugano, Switzerland. The early termination reduced the lease term by 9 years and8* months thus ending on* April 30, 2024.Our lease liability and Right of Use asset were both decreased by approximately $0.3 million as a result of the early termination of the lease agreement. On January 22, 2024,we entered into a lease for a new apartment in Lugano, Switzerland. This lease is for an initial term of 27 months beginning April 1, 2024and ending on June 30, 2026.*

Minimum rental commitments (exclusive of property tax, insurance and maintenance) under all non-cancelable operating leases with initial or remaining lease terms in excess ofone year, including the lease agreements referred to above, are set forth below as of* June 30, 2025* (in thousands):

Rental expense totaled $5.5 million for the fiscal year ended* June 30, 2025* and $5.4 million for the fiscal year ended* June 30, 2024*.

K. Economic Dependency

We had substantial net sales to certain customers in our private-label contract manufacturing segment during the fiscal years ended* June**30* shown in the following table. The loss of any of these customers, or a significant decline in sales or the growth rate of sales to these customers, or in their ability to make payments when due, could have a material adverse impact on our net sales and net operating results. Net sales to anyone customer representing10% or more of the respective year’s consolidated net sales were as follows (dollars in thousands):

Accounts receivable from these customers totaled $9.9 million at* June 30, 2025* and $12.3 million at* June 30, 2024*.

We buy certain products, including beta-alanine, from a single supplier. The loss of this supplier or other raw material suppliers could have a material adverse impact on our net results of operations. Raw material purchases from anyone supplier representing10% or more of the respective period’s total raw material purchases were as follows (dollars in thousands):

L. Derivatives and Hedging

We are exposed to gains and losses resulting from fluctuations in foreign currency exchange rates relating to forecasted product sales denominated in foreign currencies and to other transactions of NAIE, our foreign subsidiary. As part of our overall strategy to manage the level of exposure to the risk of fluctuations in foreign currency exchange rates, we* mayuse foreign exchange contracts in the form of forward contracts. There can beno* guarantee any such contracts, to the extent we enter into such contracts, will be effective hedges against our foreign currency exchange risk.

During the year ended* June 30, 2025* and prior, we entered into forward contracts designated as cash flow hedges primarily to protect against the foreign exchange risks inherent in our forecasted sales of products at prices denominated in currencies other than the U.S. dollar. These contracts are expected to be settled through* June**2026.* For derivative instruments that are designated and qualify as cash flow hedges, we record the effective portion of the gain or loss on the derivative in accumulated other comprehensive income (OCI) as a separate component of stockholders’ equity and subsequently reclassify these amounts into earnings in the period during which the hedged transaction is recognized in earnings.

For foreign currency contracts designated as cash flow hedges, hedge effectiveness is measured using the spot rate. Changes in the spot-forward differential are excluded from the test of hedge effectiveness and are recorded currently in earnings as revenue. We measure effectiveness by comparing the cumulative change in the hedge contract with the cumulative change in the hedged item as well as ensuring the assumptions we made at hedge inception havenot materially changed. No hedging relationships were terminated as a result of ineffective hedging for the years ended* June 30, 2025* and* June 30, 2024*.

We monitor the probability of forecasted transactions as part of the hedge effectiveness testing on a quarterly basis.

As of* June 30, 2025*, the notional amounts of our foreign exchange contracts accounted for as cash flow hedges were $35.5 million (€31.2 million) for Euro sales and $6.8 million (CHF 5.4 million) for Swiss Franc sales. As of* June 30, 2025*, a net loss of approximately $1.6 million offset by approximately $0.4 million of deferred taxes, related to derivative instruments designated as cash flow hedges was recorded in OCI. As of* June 30, 2024*, a net gain of approximately $0.2 million, offset by approximately $0.1 million of deferred taxes, related to derivative instruments designated as cash flow hedges was recorded in OCI. It is expected that $1.6 million of the net loss as of* June 30, 2025*, will be reclassified into earnings in the next12 months along with the earnings effects of the related forecasted transactions.

38

During the year ended* June 30, 2025*, we recognized $1.6 million of net losses in OCI and reclassified $0.2 million of net losses and forward point amortization from OCI to Net Sales. During the year ended* June 30, 2024*, we recognized $0.8 million of net gains in OCI and reclassified $0.4 million of gains and forward point amortization from OCI to Net Sales.

For foreign currency contractsnot designated as cash flow hedges, changes in the fair value of the hedge are recorded directly to foreign exchange gain or loss in other income in an effort to offset the change in valuation of the underlying hedged item. During the year ended* June 30, 2025*, we entered into forward contracts in order to hedge foreign exchange risk associated with our lease liability at NAIE, which is denominated in Swiss Francs (CHF). As of* June 30, 2025*, the notional amounts of our foreign exchange contractsnot designated as cash flow hedges were approximately $11.8 million (CHF 9.5 million).

We are exposed to interest rate fluctuations related to our $10.0 million Term Note with Wells Fargo, which carries a variable interest rate of 1.80% above the SOFR rolling30-day average. To manage our exposure to this variable rate, on* August 23, 2021,we entered into a floored interest rate swap that fixes our all-in rate on this loan to 2.4% for thefirst* three years of the term loan. Fluctuations in the relation of our contractual swap rate to current market rates are recorded as an asset or liability with an offset to OCI at the end of each reporting period. Interest expense is adjusted for the difference between the actual SOFR spread and the swap contractual rate such that our effective interest expense for each period is equal to our hedged rate of2.4%. This interest rate swap contract expired on* September 3, 2024.*

M. Contingencies

From time to time, we become involved in various investigations, claims and legal proceedings that arise in the ordinary course of our business. These matters* mayrelate to product liability, employment, intellectual property, tax, regulation, contract or other matters. The resolution of these matters as they arise will be subject to various uncertainties and, even if such claims are without merit, could result in the expenditure of significant financial and managerial resources. While unfavorable outcomes are possible, based on available information, we generally donot* believe the resolution of these matters will result in a material adverse effect on our business, consolidated financial condition, or results of operations and the price of our common stock. However, a settlement payment or unfavorable outcome could adversely impact our results of operations. Our evaluation of the likely impact of these actions could change in the future and we could have unfavorable outcomes we donot expect.

Settlement of Legal Proceeding

In* December 2023,we were sued bythree* former employees intwo separate, but substantially identical matters brought by the same law firm. The lawsuits were filed as a putative class action and a PAGA action seeking awards for all similarly situated employees going backten years or more. We responded to these actions and agreed to submit the matters for mediation. On* July 3, 2025,the mediation took place, and a tentative settlement agreement was reached whereby we agreed to contribute a maximum of $1.25 million. We have joined with the plaintiffs in moving the court to consolidate thetwo* actions. The potential settlement has been brought before the court and all similarly situated employees need to be contacted, and they* mayelect to participate ornot.* The process of obtaining court approval of the settlement is estimated to take approximatelyone year. We accrued the maximum settlement amount in our results of operations as of* June 30, 2025* along with estimated related legal fees of approximately $0.15 million.

Employee Retention Tax Credit

In fiscal2023, we recorded a $3.5 million Employee Retention Tax Credit ("ERTC") net refund associated with the Coronavirus Aid, Relief, and Economic Security Act signed into law in* March 2020and extended with the Taxpayer Certainty and Disaster Tax Relief Act of2020* and the American Rescue Plan Act of2021. These acts provided numerous tax provisions and other stimulus measures, including the ERTC. Under these expanded measures, we determined during fiscal2023 that we qualified for the ERTC for thefirst three quarters of calendar2021 and filed the required amended payroll tax returns to claim this refund. On* December 9, 2024,the Internal Revenue Service ("IRS") sent us a105c* letter informing us that they donot believe we qualify for the tax credit for thethird quarter of calendar2021. We disagreed with the position the IRS noted in their denial letter and responded to their letter to contest their claim. Although we had received this initial denial from the IRS, we believe we were entitled to the refund for these claims and therefore we havenot made any allowances against the accrual for the related refund that was recorded in fiscal2023. We havenot yet received any additional correspondence from the IRS associated with our appeal related to thethird quarter of calendar2021, but in* April 2025,we collected the refund amounts associated with our ERTC filings for thefirst* andsecond quarters of calendar year2021, which totaled $2.9 million.

Geopolitical Uncertainty

Management is monitoring the war in Ukraine, and the armed conflicts in Gaza, Lebanon and Syria, and potential economic effects from these events as they develop. These geographical areas account for a small portion of our global net sales, but we do source multiple raw materials from Israel. We donot anticipate these conflicts will have a significant impact on our net sales. We are continually evaluating options for alternative ingredient sources and/or holding safety stock of impacted materials to limit any impact. There are further concerns regarding consumer purchasing and consumption behavior, increases in global shipping expenses, greater volatility in foreign exchange and interest rates, and other unforeseen business disruptions due to the current global geopolitical tensions. We will continue to evaluate impacts of these developments on our customers, suppliers, employees, and operations.

Government Trade Tariffs

The President of the United States has recently ordered U.S. government agencies to enforce new and increased tariffs on a wide range of goods and materials imported from foreign trade partners. Some tariffs have been presently deferred, and details of future tariff restrictions continuously evolve. Current and future implementation of tariffs* mayinclude products and ingredients we or our customers require for their products. These goods mayinclude beta-alanine. The commercialization of our beta-alanine patent estate depends on the availability of the raw material beta-alanine. In response, China and other governments have imposed tariffs on certain American products. The resulting tariffs could have a significant adverse effect on our customers' businesses, the availability of beta-alanine, and the cost of our products. While we donot* know how potential increased tariffs will be imposed, or how any tariffs will impact our business, we believe the imposition of additional tariffs by the U.S. or other governments on products or ingredients we use in the products we manufacture could adversely impact our customers as a result of increased product costs, and such increased costs could have an adverse impact on the availability of beta-alanine, the licensing of our patents and trademarks and our distribution of this raw material. This could adversely impact our ability to license our patents and trademarks, our ability to sell beta-alanine, and our customers’ ability to compete in the marketplace, reducing demand for our products, and products we manufacture for our customers. Any of these events could have a material adverse effect on our business and results of operations.

As a contract manufacturer, we pass through material cost increases to our customers, including increases associated with tariffs. We also work with our customers to identify potential alternative supply sources for key ingredients to help mitigate the impact tariffs* may*have on the cost of their products. We will continue to evaluate the impact of imposed trade tariffs on our customers, suppliers and operations.

39

N. Segment Information

Our business consists oftwo segments for financial reporting purposes. Thetwo segments are identified as (i) private-label contract manufacturing, which primarily relates to the provision of private-label contract manufacturing services to companies that market and distribute nutritional supplements and other health care products, and (ii) patent and trademark licensing, which primarily includes direct raw material sales and royalty income from our license and supply agreements associated with the sale and use of beta-alanine under our CarnoSyn® and SR CarnoSyn® trade names and TriBsyn™ trademark.

The chief operating decision maker is the Company's Chief Executive Officer, who, in conjunction with senior management, evaluates segment performance based on a number of factors. The primary performance measures for each segment are net sales and income or loss from operations before corporate allocations. Operating income or loss for each segment doesnot include corporate general and administrative expenses, interest expense and other miscellaneous income and expense items. Corporate general and administrative expenses include, but arenot limited to human resources, corporate legal, finance, information technology, and other corporate level related expenses, which arenot allocated to any segment. Transfers of raw materials between segments are recorded at cost. The accounting policies of our segments are the same as those described in the summary of significant accounting policies in Note A.

Our operating results by business segment for the year ended* June 30, 2025* were as follows (in thousands):

40

Our operating results by business segment for the year ended* June 30, 2024* were as follows (in thousands):

Our private-label contract manufacturing products are sold both in the U.S. and in markets outside the U.S., including Europe, Canada, Australia, New Zealand, Mexico and Asia. Our primary markets outside the U.S. are Europe and Asia. Our patent and trademark licensing activities are primarily based in the U.S.

Net sales by geographic region, based on the customers’ location, for thetwo years ended* June**30* were as follows (in thousands):

Products manufactured by NAIE accounted for 85% of consolidated net sales in markets outside the U.S. in fiscal2025 and 79% of consolidated net sales in markets outside the U.S. in fiscal2024. No products manufactured by NAIE were sold in the U.S. during the fiscal years ended* June 30, 2025and2024*.

Long-lived assets by geographic region, based on the location of the company or subsidiary at which they were located or made, for thetwo years ended* June**30* were as follows (in thousands):

Total assets by geographic region, based on the location of the company or subsidiary at which they were located or made, for thetwo years ended* June**30* were as follows (in thousands):

Capital expenditures by geographic region, based on the location of the company or subsidiary at which they were located or made, for thetwo years ended* June**30* were as follows (in thousands):

41